Tesamorelin (10mg)

Pharmaceutical-grade research peptide, lyophilized for stability. Each batch is independently tested and COA-verified with ≥99% purity by HPLC analysis. Intended exclusively for research purposes.

Tesamorelin is studied as a GHRH analogue primarily in the context of HIV-associated abdominal fat accumulation and lipodystrophy. Research examines body composition, IGF-1 response, lipids, liver fat, glucose parameters and quality of life. Tesamorelin stimulates endogenous GH release via the GHRH pathway, which distinguishes it from direct growth hormone administration. The literature also addresses safety aspects including IGF-1 elevation, glucose homeostasis and long-term effects.

For laboratory research use only. This information describes areas of scientific investigation and does not constitute medical advice, dosing guidance or therapeutic claims.